Results 161 to 170 of about 12,296,497 (289)

Estimation of common breaks in linear panel data models via screening and ranking algorithm. [PDF]

Sci Rep
Li F, Xiao Y, Chen Z.
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Perspective review: Will generative AI make common data models obsolete in future analyses of distributed data networks? [PDF]

Ther Adv Drug Saf
Painter JL, Ramcharran D, Bate A.
europepmc   +1 more source

Use of spatial panel-data models to investigate factors related to incidence of end-stage renal disease: a nationwide longitudinal study in Taiwan. [PDF]

BMC Public Health, 2023
Su CC, Lee KJ, Yen CT, Wu LH, Huang CH, Lu MZ, Cheng CL.   +6 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Data, Models, and Visuals: How Data Science Methods Can Augment (Geriatric) Oncology Research. [PDF]

J Clin Oncol
Ramsdale E, Mohile S.
europepmc   +1 more source

Evidence-Based Data Models for Return-to-Play Criteria after Anterior Cruciate Ligament Reconstruction. [PDF]

Healthcare (Basel), 2022
Daggett MC, Witte KA, Cabarkapa D, Cabarkapa DV, Fry AC.   +4 more
europepmc   +1 more source

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

National COVID Cohort Collaborative data enhancements: a path for expanding common data models. [PDF]

J Am Med Inform Assoc
Walters KM, Clark M, Dard S, Hong SS, Kelly E, Kostka K, Lee AM, Miller RT, Morris M, Palchuk MB, Pfaff ER, N3C and RECOVER Consortia.   +11 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source